Business Wire

Takeda Global Headquarters Grand Opening

Share

Takeda Pharmaceutical Company Limited, (“Takeda”) (TOKYO:4502) today held the grand opening of Takeda Global Headquarters. The building, completed in March 2018, will serve as Takeda's head office for its operations worldwide.

At the grand opening, Creative Director Kashiwa Sato (SAMURAI, Inc.), Takeda's President and CEO Christophe Weber, and Takeda’s Head of Corporate Strategy and the CEO Office, Yasuhiro Fukutomi, who managed the project, took to the stage to introduce the objectives and significance of the project as the company accelerates its transformation.

“Takeda Global Headquarters symbolizes the passing on to the next generation of Takeda's unwavering identity and values as a company, with its roots in Japan, yet reaching patients worldwide," said Takeda President and CEO Weber. "Moreover, it will provide a base for our diverse workforce of around 30,000 employees across the globe where they can connect, collaborate, learn and share, in an environment designed to offer comfort and inspiration. From here in Nihonbashi, Tokyo, we will pursue our mission of contributing to better health and a brighter future for people worldwide, while nurturing our relationship with the local community.”

Kashiwa Sato said “I wanted the design of Takeda’s new headquarters to express the essence of Takeda’s values, and its core commitment to always put patients first. In this process, I chose 'life force' as the central concept, and the eight characters for 'life', 'water', 'light', 'earth', 'trees', 'people', 'connections', and 'future' as motifs, representing this concept. Just as these basic natural elements form the wellspring that nurtures life, the bonds between people are the driving-force that enable them to tackle the biggest of challenges, and contribute to a brighter future for all. It is my hope that this building will be an inspiration to all who work here as well as to the visitors, and it will lead them to naturally want to share their thoughts on Takeda’s future.”

With Takeda Global Headquarters as a base, and a symbol of our values, we will further accelerate our transformation into becoming a global, values-based R&D-driven biopharmaceutical leader.

About Takeda Global Headquarters

Please visit the URL below for more information on Takeda Global Headquarters.
https://www.takeda.com/who-we-are/how-we-work/

Design Concept

As the embodiment of a global brand with roots in Japan, I wanted the design of Takeda’s new headquarters to express the essence of Takeda’s DNA. These fundamental elements contribute to Takeda being the world-renowned pharmaceutical company, as well as underpinning the promise of a brighter future for all. They could also be interpreted as people’s “life force”, and it was this that I selected as the overall concept for the interior design. The concept of “life force” can also be seen to represent the fundamental point of origin of the company, and indeed, refined to reveal a vision of its future state. In this way, it can hold an important message for Takeda, and one that should be embraced and passed on to future generations. I approached the flow of movement, from the building entrance, past the reception and then on to the areas where people work, as a story of nurturing life. I chose to depict phases in this story - beginning with the source of life, followed by growth, and finally to the formation of strong connections - by associating symbolic kanji characters with each space. The characters were tuned into modern designs that convey the spirit of ”Wa” (a sense of Japanese-style harmony) which is inherent in Takeda, and applied as artwork on the walls. It is my hope that this building will be an inspiration to all who work here, and will lead them to naturally want to share their thoughts on Takeda’s future with other people that they meet on a daily basis.

Kashiwa Sato, Creative Director
http://kashiwasato.com/

Photos are available upon request.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TOKYO: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi, +81 (0) 3-3278-2095
kazumi.kobayashi@takeda.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 10:15:00 EEST | Press release

Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i

Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 10:00:00 EEST | Press release

Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vice President, Skechers Technical Performance Division. “An evolution of our legacy in running, Skechers AERO was d

The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 10:00:00 EEST | Press release

Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP and Optical Transport, Mobile Networks, Mobile Services, and Data Centres. “Network X is more than a conference—it

4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 08:00:00 EEST | Press release

4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P004. “Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis,” said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. “Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. B

Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 20:06:00 EEST | Press release

Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The company’s global headquarters includes WPC certified test equipment and state-of-the-art test labs dedicated to full product lifecycle validatio

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye